Pharmacological antagonists of some of these transforming genes (e.g., EGFR inhibitors) could reduce TF expression, both locally and systemically, and these targeted agents are considered as potential indirect and cancer-specific anticoagulants, in addition to their direct antitumor effects38. The gene discussed is EGFR; the disease is cancer.